Document is current
Any future updates will be listed below
-
Authors
Parissenti, Amadeo M.
Pritzker, Laura B.
Dahle, Maria Aanesland
Gythfeldt, Hedda von der Lippe
Masilamani, Twinkle
Theriault, Gabriel
St-Onge, Renée
D’costa, Lavina
Lingjaerde, Ole Christian
Haugen, Mads Haugland
Engebraaten, Olav
-
Funding
Funding for this research was provided by:
Norther Cancer Foundation
RNA Diagnostics, Inc.
University of Texas MD Anderson Cancer Center (P30CA016672 and R50CA221675)
Roche Norway
Sanofi-Aventis
Norwegian Breast Cancer Society (11003001)
Norwegian Research Council (191436/V50)
K. G. Jebsen Center for Breast Cancer Research (2020072)
South-Eastern Norway Regional Health Authority (2024099)
- License Information
-
More Information
Article History
Received: 23 March 2025
Accepted: 23 July 2025
First Online: 11 August 2025
Declarations
:
: The NeoAva trial was approved by the Institutional Protocol Review Board, regional research ethics committees, and the Norwegian Medicines Agency. The trial was conducted in accordance with the Declaration of Helsinki International Conference on Harmonization Good Clinical Practice. All patients provided informed consent prior to inclusion in the NeoAva clinical trial.
: All patients agreed to the sharing and publication of pseudonymized data. All authors reviewed the manuscript and consented to its submission for publication.
: Some authors declare significant conflicts of interest, which did not impact on study design or interpretation. L.B.P., T.M., R.S., G.T. and L.D. are/were employees of Rna Diagnostics, which seeks to introduce the RDA into the oncology marketplace. A.M.P. and L.B.P. are minority shareholders in the company. A.M.P. receives research support from Rna Diagnostics. O.E. received research support from Roche Norway and Sanofi-Aventis, who helped fund the NeoAva trial. The remaining authors declare no conflicts of interest.
